MAAT — Maat Pharma SA Balance Sheet
0.000.00%
- €82.75m
- €78.49m
- €3.22m
Annual balance sheet for Maat Pharma SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 19.9 | 43.3 | 35.3 | 24.3 | 20.2 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 1.94 | 3.33 | 4.68 | 5.04 | 5.95 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 22.2 | 47.3 | 42.1 | 32 | 27.6 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 1.1 | 1.11 | 0.966 | 9.17 | 8.6 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 24.3 | 49.4 | 44.7 | 42.9 | 38.5 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.86 | 4.7 | 9.22 | 11.5 | 14.6 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 8.34 | 9.56 | 17.9 | 22.5 | 28.2 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 15.9 | 39.9 | 26.8 | 20.5 | 10.3 |
Total Liabilities & Shareholders' Equity | 24.3 | 49.4 | 44.7 | 42.9 | 38.5 |
Total Common Shares Outstanding |